No Data
No Data
No Data
No Data
No Data
Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
Yahoo FinanceApr 19 10:00 ET
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive in
BenzingaApr 18 11:00 ET
Regeneron Pharma Price Target Raised to $1099.00/Share From $1090.00 by UBS
Regeneron Pharma Price Target Raised to $1099.00/Share From $1090.00 by UBS
Dow JonesApr 18 07:43 ET
Regeneron Pharma Is Maintained at Buy by UBS
Regeneron Pharma Is Maintained at Buy by UBS
Dow JonesApr 18 07:43 ET
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Tuesday, Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD). Tezspire is a re
BenzingaApr 17 14:39 ET
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.99% on an annualized basis producing an average annual return of 22.65%. Currently, Regeneron Pharmaceu
BenzingaApr 17 13:00 ET
Strike freedom : Don’t have akebia?
MeltyyOP Strike freedom: the first of the post
Strike freedom MeltyyOP: I mean in the April calendar
Srav Reddy : Wonder why $Akebia Therapeutics (AKBA.US)$ dropped after PDUFA
No Data
No Data